Literature DB >> 20093533

Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE.

Dong Gwon1, Gi-Young Ko, Hyun-Ki Yoon, Kyu-Bo Sung, Jin Hyoung Kim, Seung Soo Lee, Jae Myeong Lee, Joon-Young Ohm, Ji Hoon Shin, Ho-Young Song.   

Abstract

PURPOSE: To analyze the characteristics associated with membranous obstruction of the inferior vena cava (MOVC)-associated hepatocellular carcinoma (HCC) and to evaluate the clinical efficacy of transcatheter arterial chemoembolization (TACE).
MATERIALS AND METHODS: This retrospective study was approved by an institutional review board, and informed consent was waived. Ninety-eight patients (mean age, 48.5 years +/- 12.9 [standard deviation]) with MOVC were retrospectively evaluated. The diagnosis of Budd-Chiari syndrome was confirmed with results from Doppler ultrasonography, computed tomography, magnetic resonance imaging, and/or inferior venacavography. The cumulative incidences of HCC and the patient survival period were calculated by using the Kaplan-Meier method. Factors associated with the development of HCC were evaluated by using multivariate Cox regression analysis.
RESULTS: Among 98 patients with MOVC, liver nodules were detected in 37 patients (38%), 23 of whom had HCC associated with MOVC and 14 of whom had benign nodules. The cumulative incidence of HCC at 1, 5, and 10 years was 7.3%, 13.5%, and 31.8%, respectively. Female sex was the only significant factor associated with the development of HCC (odds ratio, 6.02; P <.001). HCC was of the single nodular type and of peripheral location. Among 23 patients with HCC, 20 patients were treated with only TACE and three with liver transplantation after TACE. After TACE, 14 (61%) of the study patients had a complete response, and survival rates at 1, 2, 3, 4, and 5 years were 90%, 85%, 61%, 61%, and 46%, respectively.
CONCLUSION: The incidence of HCC in patients with MOVC was similar to that found in other studies. TACE resulted in an effective tumor response for HCC and seemed to be effective in prolonging patient survival. Female sex was the only significant factor associated with the development of HCC. A single nodular tumor with a peripheral location appears to have a higher probability of HCC.

Entities:  

Mesh:

Year:  2010        PMID: 20093533     DOI: 10.1148/radiol.09090738

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

1.  Studies on Budd-chiari syndrome complicated with hepatocellular carcinoma: most patients without inferior vena cava obstruction.

Authors:  Xiaowei Dang; Luhao Li; Suxin Li; Yafei Wang; Hai Li; Shaokai Xu; Peiqin Xu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  Liver cirrhosis in hepatic vena cava syndrome (or membranous obstruction of inferior vena cava).

Authors:  Santosh Man Shrestha
Journal:  World J Hepatol       Date:  2015-04-28

3.  Management of hepatocellular carcinoma: Enlightening the gray zones.

Authors:  Andrea Mancuso
Journal:  World J Hepatol       Date:  2013-06-27

4.  Redefining Budd-Chiari syndrome: A systematic review.

Authors:  Naomi Shin; Young H Kim; Hao Xu; Hai-Bin Shi; Qing-Qiao Zhang; Jean Paul Colon Pons; Ducksoo Kim; Yi Xu; Fei-Yun Wu; Samuel Han; Byung-Boong Lee; Lin-Sun Li
Journal:  World J Hepatol       Date:  2016-06-08

Review 5.  Hepatocellular nodules in vascular liver diseases.

Authors:  Christine Sempoux; Charles Balabaud; Valérie Paradis; Paulette Bioulac-Sage
Journal:  Virchows Arch       Date:  2018-05-26       Impact factor: 4.064

Review 6.  Budd-Chiari syndrome/hepatic venous outflow tract obstruction.

Authors:  Dominique-Charles Valla
Journal:  Hepatol Int       Date:  2017-07-06       Impact factor: 6.047

Review 7.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

8.  Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience with long-term follow-up in South Korea.

Authors:  Hana Park; Jin Young Yoon; Kyeong Hye Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

9.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

10.  Noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Han Chu Lee
Journal:  Clin Mol Hepatol       Date:  2012-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.